National Institute for Occupational Safety and Health (NIOSH), Safety and Occupational Health Study Section (SOHSS); Notice of Charter Renewal, 43839-43840 [2020-15617]
Download as PDF
<![CDATA[
43839
Federal Register / Vol. 85, No. 139 / Monday, July 20, 2020 / Notices
other forms of information technology,
e.g., permitting electronic submission of
responses; and
(e) Assess information collection
costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570.
Comments and recommendations for the
proposed information collection should
be sent within 30 days of publication of
this notice to www.reginfo.gov/public/
do/PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function. Direct written
comments and/or suggestions regarding
the items contained in this notice to the
Attention: CDC Desk Officer, Office of
Management and Budget, 725 17th
Street NW, Washington, DC 20503 or by
fax to (202) 395–5806. Provide written
comments within 30 days of notice
publication.
Proposed Project
Injection Drug Use Surveillance
Project—New—National Center for HIV/
AIDS, Viral Hepatitis, STD, and TB
Prevention (NCHHSTP), Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
The purpose of the Injection Drug Use
(IDU) Surveillance Project (IDU–SP) is
to develop a surveillance system to
monitor drug use risk and prevention
behaviors and the infectious disease
consequences of high-risk drug use in
6–30 select urban and non-urban areas
of the U.S. that have been impacted by
the opioid crisis. Such a surveillance
system is needed to inform prevention
efforts and policy. The specific
objectives of the project are to assess the
following among persons who use drugs
(i.e., via injecting and non-injecting
routes of administration) who are
recruited in syringe services programs
(SSPs) and through peer-driven
recruitment: (1) Drug use and sex risk
behaviors, injection risk networks,
receipt of prevention services, and
barriers to prevention and care; and (2)
the prevalence of HIV and Hepatitis C
(HCV) infections.
The project will involve a two-stage
sampling approach. First, 6–30 SSPs
will be selected to ensure geographic
diversity and representation of key
program characteristics, such as syringe
distribution model (needs-based vs all
other) and length in operation (<5 years,
5 years or longer). Second, SSP clients
and their drug using peers will be
recruited through a combination of
random recruitment at SSP and social
network strategy to partake in a survey
and HCV and HIV testing. Clients of
SSPs and their peers who meet
eligibility criteria will complete a
survey using the Research Electronic
Data Capture (REDCap) system, a secure
web-based application for administering
online surveys. The survey will include
questions on drug use and sex risk
behaviors, risk networks, transitions
from non-injection drug use to drug
injection, drug treatment history, history
of drug use related adverse health
outcomes, such as overdose,
experiences with law enforcement,
experiences with violence and access,
HIV and HCV testing experience, and
use of prevention and health care
services. Lastly, participants will be
offered anonymous HIV and HCV
testing in conjunction with the survey,
which they may refuse with no effect on
participation in the survey.
Approximately 10,500 individuals
will complete the eligibility screening
form. Our target population is 300
participants per site or 9,000 for up to
30 sites. We anticipate that, on average,
16.66% or 1,499 persons (for up to 30
SSPs) will not be interested in
completing a survey, yielding a
maximum of 10,499 eligible
participants. The total annualized
burden is 6,125 hours. There are no
other costs to respondents other than
their time.
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Respondent
Form name
Persons Screened ..........................................
Persons who give permission .........................
Eligible Participants .........................................
Eligibility Screening Form ..............................
Model Project Permission Form .....................
IDU Survey .....................................................
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2020–15654 Filed 7–17–20; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
National Institute for Occupational
Safety and Health (NIOSH), Safety and
Occupational Health Study Section
(SOHSS); Notice of Charter Renewal
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of charter renewal.
AGENCY:
This gives notice under the
Federal Advisory Committee Act of
October 6, 1972, that the Safety and
Occupational Health Study Section,
Centers for Disease Control and
SUMMARY:
VerDate Sep<11>2014
19:11 Jul 17, 2020
Jkt 250001
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
10,499
9,000
9,000
Number of
responses
per
respondent
Average
burden per
response
(hours)
1
1
1
5/60
5/60
30/60
Prevention, Department of Health and
Human Services, has been renewed for
a 2-year period through June 30, 2022.
FOR FURTHER INFORMATION CONTACT:
Joanne Fairbanks, Designated Federal
Officer, Safety and Occupational Health
Study Section, Department of Health
and Human Services, 1600 Clifton Road
NE, Mailstop E74, Atlanta, Georgia
30329–4027, telephone (304) 285–6143
or fax (304) 285–6147.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
E:\FR\FM\20JYN1.SGM
20JYN1
43840
Federal Register / Vol. 85, No. 139 / Monday, July 20, 2020 / Notices
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2020–15617 Filed 7–17–20; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day-20–0109; Docket No. CDC–2020–
0080]
Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), as part of
its continuing effort to reduce public
burden and maximize the utility of
government information, invites the
general public and other Federal
agencies the opportunity to comment on
a proposed and/or continuing
information collection, as required by
the Paperwork Reduction Act of 1995.
This notice invites comment on a
proposed information collection project
titled Respiratory Protective Devices—
42 CFR part 84—Regulation. The
purpose of the data collection is to
enable 42 CFR part 84 respirator
approval certification activities.
DATES: CDC must receive written
comments on or before September 18,
2020.
SUMMARY:
You may submit comments,
identified by Docket No. CDC–2020–
0080 by any of the following methods:
• Federal eRulemaking Portal:
Regulations.gov. Follow the instructions
for submitting comments.
• Mail: Jeffrey M. Zirger, Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, MS–D74, Atlanta,
Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. CDC will post, without
change, all relevant comments to
Regulations.gov.
Please note: Submit all comments
through the Federal eRulemaking portal
(regulations.gov) or by U.S. mail to the
address listed above.
ADDRESSES:
VerDate Sep<11>2014
18:30 Jul 17, 2020
Jkt 250001
To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact Jeffrey M. Zirger,
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE, MS–
D74, Atlanta, Georgia 30329; phone:
404–639–7570; Email: omb@cdc.gov.
SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), Federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. In addition, the PRA also
requires Federal agencies to provide a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each new
proposed collection, each proposed
extension of existing collection of
information, and each reinstatement of
previously approved information
collection before submitting the
collection to the OMB for approval. To
comply with this requirement, we are
publishing this notice of a proposed
data collection as described below.
The OMB is particularly interested in
comments that will help:
1. Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
2. Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and
clarity of the information to be
collected; and
4. Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submissions
of responses.
5. Assess information collection costs.
FOR FURTHER INFORMATION CONTACT:
Proposed Project
Respiratory Protective Devices—42
CFR part 84—Regulation (OMB Control
No. 0920–0109, Exp. 10/31/20)—
Revision—National Institute for
Occupational Safety and Health
(NIOSH), Centers for Disease Control
and Prevention (CDC).
Background and Brief Description
The regulatory authority for the
National Institute for Occupational
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
Safety and Health (NIOSH) certification
program for respiratory protective
devices is found in the Mine Safety and
Health Amendments Act of 1977 (30
U.S.C. 577a, 651 et seq., and 657(g)) and
the Occupational Safety and Health Act
of 1970 (30 U.S.C. 3, 5, 7, 811, 842(h),
844). These regulations have, as their
basis, the performance tests and criteria
for approval of respirators used by
millions of American construction
workers, miners, painters, asbestos
removal workers, fabric mill workers,
and fire fighters.
Regulations of the Environmental
Protection Agency (EPA) and the
Nuclear Regulatory Commission (NRC)
also require the use of NIOSH-approved
respirators. These regulations also
establish methods for respirator
manufacturers to submit respirators for
testing under the regulation and have
them certified as NIOSH-approved if
they meet the criteria given in the above
regulation. This data collection was
formerly named Respiratory Protective
Devices 30 CFR part 11 but in 1995, the
respirator standard was moved to 42
CFR part 84.
NIOSH, in accordance with 42 CFR
part 84: (1) Issues certificates of
approval for respirators which have met
specified construction, performance,
and protection requirements; (2)
establishes procedures and
requirements to be met in filing
applications for approval; (3) specifies
minimum requirements and methods to
be employed by NIOSH and by
applicants in conducting inspections,
examinations, and tests to determine
effectiveness of respirators; (4)
establishes a schedule of fees to be
charged applicants for testing and
certification, and (5) establishes
approval labeling requirements.
Information is collected from those who
request services under 42 CFR part 84
in order to properly establish the scope
and intent of request.
Information collected from requests
for respirator approval functions
includes contact information and
information about factors likely to affect
respirator performance and use. Such
information includes, but is not
necessarily limited to, respirator design,
manufacturing methods and materials,
quality assurance plans and procedures,
and user instruction and draft labels, as
specified in the regulation.
The main instrument for data
collection for respirator approval
functions is the Standard Application
Form for the Approval of Respirators
(SAF), currently Version 9. Respirator
manufacturers are the respondents
(estimated to average 140 each year over
the years 2020–2023) and upon
E:\FR\FM\20JYN1.SGM
20JYN1
]]>Agencies
[Federal Register Volume 85, Number 139 (Monday, July 20, 2020)]
[Notices]
[Pages 43839-43840]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-15617]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
National Institute for Occupational Safety and Health (NIOSH),
Safety and Occupational Health Study Section (SOHSS); Notice of Charter
Renewal
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of charter renewal.
-----------------------------------------------------------------------
SUMMARY: This gives notice under the Federal Advisory Committee Act of
October 6, 1972, that the Safety and Occupational Health Study Section,
Centers for Disease Control and Prevention, Department of Health and
Human Services, has been renewed for a 2-year period through June 30,
2022.
FOR FURTHER INFORMATION CONTACT: Joanne Fairbanks, Designated Federal
Officer, Safety and Occupational Health Study Section, Department of
Health and Human Services, 1600 Clifton Road NE, Mailstop E74, Atlanta,
Georgia 30329-4027, telephone (304) 285-6143 or fax (304) 285-6147.
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been delegated the authority to sign Federal Register notices
pertaining to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and
[[Page 43840]]
Prevention and the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2020-15617 Filed 7-17-20; 8:45 am]
BILLING CODE 4163-18-P
